|
Ukrain, an alkaloid thiophosphoric acid derivative of Chelidonium majus L. protects human fibroblasts but not human tumour ce |
80.00% |
|
Chemical analyses of Ukrain, a semi-synthetic Chelidonium majus alkaloid derivative, fail to confirm its trimeric structure |
90.00% |
|
NF-kappaB does not influence the induction of apoptosis by Ukrain. |
70.00% |
|
Ukrain (NSC-631570) in the treatment of pancreas cancer. |
95.00% |
|
Ukrain (NSC-631570) influences on bone status: a review. |
50.00% |
|
71 year old woman, Pancraetic cancer with liver and lung metastasis. |
90.00% |
|
A comparative evaluation of the influence of the complex drug Ukrain and its components on the effects of radiation |
80.00% |
|
A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study |
50.00% |
|
A study of the influence of a novel drug Ukrain on in vivo effects of low-dose ionizing radiation |
50.00% |
|
Animal studies on Ukrain |
65.00% |
|
Antinociceptive effect of ten day administration of Ukrain in mice and interaction of the treatment with morphine |
80.00% |
|
Bcl-2 overexpression protects human keratinocyte cells from Ukrain-induced apoptosis but not from G2/M arrest. |
60.00% |
|
Biological activity of some thiophosphamide derivatives of alkaloids with respect to influenza virus |
50.00% |
|
Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report) |
60.00% |
|
Chelidonium majus L. (Ukrain) in the treatment of cancer patients. |
63.33% |
|
Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain. |
20.00% |
|
Clinical Investigations on Ukrain |
90.00% |
|
Clinical studies of Ukrain in healthy volunteers (phase 1). |
60.00% |
|
Clinical studies of Ukrain in terminal cancer patients (phase II) |
80.00% |
|
Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report) |
60.00% |
|
Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies.... |
50.00% |
|
Comparative evaluation of the complex treatment of rectal cancer patients (chemotherapy and X-ray therapy, Ukrain monotherapy) |
80.00% |
|
Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. |
65.00% |
|
Comparative in vitro study of the effects of the new antitumor drug Ukrain and several cytostatic agents on the thiol groups in |
50.00% |
|
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer |
80.00% |
|
Cystatin C in LS lymphosarcoma and HA-1 hepatoma treated with Ukrain and cyclophosphamide and involvement of apoptosis. |
90.00% |
|
Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. |
30.00% |
|
Cysteine proteinases and their inhibitors in the development of mouse HA-1 hepatoma and antineoplastic therapy |
60.00% |
|
Debate in Lancet about setting up a phase II trial on Ukrain in England |
90.00% |
|
Does the Ukrain preparation protect mice against lethal doses of bacteria? |
60.00% |
|
Effect of alkaloid sanguinarine and a pharmaceutical preparation ukrain on modulation of vesicular membrane fusion and actin.... |
50.00% |
|
Effect of some isoquinoline alkaloids on enzymatic activity of acetylcholinesterase and monoamine oxidase |
80.00% |
|
Effect of Ukrain on human liver alcohol dehydrogenase activity in vitro. |
|
|
Effect of Ukrain on matrix metalloproteinase-2 and Secreted Protein Acidic and Rich in Cysteine (SPARC) expression in human.... |
80.00% |
|
Effect of Ukrain on the efficacy of anti-epileptic drugs against maximal electroshock-induced seizures in mice. |
30.00% |
|
Effect of Ukrain on the growth and metastasizing of Lewis carcinoma in C57BL/6 mice |
90.00% |
|
Efficacy of ukrain in the treatment of pancreatic cancer. |
70.00% |
|
Enhancement of macrophage tumouricidal activity by the alkaloid derivative |
40.00% |
|
Evaluation of mutagenic, genotoxic and transforming properties of Ukrain |
|
|
Evaluation of Ukrain as an immunostimulant in patients with various carcinomas. |
63.33% |
|
Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells |
60.00% |
|
In-vitro toxicity of Ukrain against human Ewing tumor cell lines. |
90.00% |
|
Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. |
|
|
Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain |
80.00% |
|
Induction of apoptosis in cultured Chinese hamster ovary cells by Ukrain and its synergistic action with etoposide. |
80.00% |
|
Influence of Ukrain on the nuclear thyroid hormone receptors after short-term gamma-irradiation. |
50.00% |
|
Inhibition of liver mitochondrial monoamine oxidase activity by alkaloids isolated from Chelidonium and Macleaya and by their de |
80.00% |
|
Interaction between Ukrain and Naltrexone in the writhing syndrome test in mice |
80.00% |
|
Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid |
55.00% |
|
Modification of antinociceptive action of morphine by Ukrain in rodents |
50.00% |
|
Morphometric and kinetic analysis of the growth of experimental sarcoma-45 in the presence of Ukrain |
50.00% |
|
National Cancer Institute, National Institute of Health: Developmental Therapeutics Program. NSC 631570: results of the Human Ce |
80.00% |
|
New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder |
60.00% |
|
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial |
85.00% |
|
Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma |
80.00% |
|
Pre-Clinical Investigations on Ukrain |
90.00% |
|
Preliminary pharmacokinetic studies of Ukrain in rats |
|
|
Preliminary results of individual therapy of chronic hepatitis C by Ukrain and interferon-alpha. |
70.00% |
|
Preliminary studies on the effect of Ukrain on the immunological response in patients with malignant tumours. |
60.00% |
|
Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. |
80.00% |
|
Radiomodification effects of Ukrain, a cytostatic and immunomodulating drug, on intracellular glucocorticoid reception during sh |
60.00% |
|
Results of Ukrain monotherapy of prostate cancer |
50.00% |
|
Retrospective study of Ukrain treatment in 203 patients with advanced-stage tumors |
90.00% |
|
Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain |
70.00% |
|
Six-week treatment with Ukrain in rabbits. Part I: Morphological parameters |
50.00% |
|
Six-week treatment with Ukrain in rabbits. Part II: Serum levels of gonadal hormones |
20.00% |
|
Six-week treatment with Ukrain in rabbits. Part III: Serum levels of thyroid hormones |
|
|
Some pharmacological properties of prolonged administration of Ukrain in rodents |
50.00% |
|
Teratological evaluation of Ukrain in hamsters and rats |
|
|
The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro. |
80.00% |
|
The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. |
75.00% |
|
The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 ... |
80.00% |
|
The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways |
70.00% |
|
The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky |
60.00% |
|
The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs |
20.00% |
|
The influence of glucose, succinate, pH of the medium and higher temperature on the cytotoxic activity of the preparation Ukrain |
80.00% |
|
The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect |
60.00% |
|
The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy |
30.00% |
|
Theoretical grounds and experimental confirmation of the antiviral effect of the |
60.00% |
|
Ukrain |
62.22% |
|
Ukrain - a new cancer cure? A systematic review of randomised clinical trials. |
90.00% |
|
Ukrain acts by inhibition of tubulin polymerization in normal and malignant cell lines. |
80.00% |
|
Ukrain both as an anti cancer and immunoregulatory agent |
60.00% |
|
Ukrain Debate 1: What is the active Substance of Ukrain? |
80.00% |
|
Ukrain in the treatment of urethral recurrent carcinoma (case report) |
50.00% |
|
Ukrain modulates glial fibrillary acidic protein, but not connexin 43 expression, and induces apoptosis in human cultured gliobl |
50.00% |
|
Ukrain monotherapy in malignant melanoma (case report) |
80.00% |
|
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report) |
40.00% |
|
Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report) |
20.00% |
|
Ukrain therapy of recurrent breast cancer with lung metastases (case report) |
80.00% |
|
Ukrain therapy of stage T1N0M0 bladder cancer patients |
60.00% |
|
Ukrain treatment in a patient with breast carcinoma |
70.00% |
|
Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. |
50.00% |
|
Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report) |
50.00% |
|
Ukrain treatment in carcinoma of the cervix (case report) |
60.00% |
|
Ukrain treatment in carcinoma of the oesophagus (case report) |
70.00% |
|
Ukrain treatment of a patient with retroperitoneal synovial sarcoma. |
35.00% |
|
Ukrain with chemotherapy in malignant melanoma (case report) |
50.00% |
|
Ukrain: acute toxicity after intravenous, intramuscular and oral administration in rats |
40.00% |
|
Ukrain: Debated Subjects |
80.00% |
